Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Myovant Sciences Ltd (MYOV)

Myovant Sciences Ltd (MYOV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,341,417
  • Shares Outstanding, K 90,149
  • Annual Sales, $ 0 K
  • Annual Income, $ -288,990 K
  • 60-Month Beta 2.62
  • Price/Sales 39.75
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MYOV with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.81
  • Number of Estimates 5
  • High Estimate -0.71
  • Low Estimate -0.91
  • Prior Year -0.79
  • Growth Rate Est. (year over year) -2.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.42 +2.83%
on 10/02/20
16.83 -18.00%
on 10/16/20
-0.25 (-1.78%)
since 09/30/20
3-Month
13.42 +2.83%
on 10/02/20
23.04 -40.10%
on 09/23/20
-2.06 (-12.99%)
since 07/30/20
52-Week
4.66 +196.17%
on 10/31/19
23.04 -40.10%
on 09/23/20
+9.15 (+196.77%)
since 10/30/19

Most Recent Stories

More News
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids

-- Seven oral and poster presentations presented at the American Society for Reproductive Medicine (ASRM) 2020 Virtual Congress

MYOV : 13.80 (-7.26%)
Myovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Ryan Crowe as vice president, investor relations. In addition to...

MYOV : 13.80 (-7.26%)
Biotech Stock Roundup: REGN's Cocktail Data, GILD's RA Drug Approval & Other Updates

The biotech sector remains in focus with regulatory and other pipeline updates.

REGN : 543.56 (-2.20%)
GILD : 58.15 (-0.65%)
VRTX : 208.36 (+0.65%)
NVAX : 80.71 (-7.90%)
MYOV : 13.80 (-7.26%)
CVAC : 48.78 (-1.65%)
Correction: Financial Markets-Stocks story

NEW YORK (AP) — In a story September 29, 2020, which included information about Myovant Sciences’ potential prostate cancer drug, The Associated Press erroneously reported that the drug failed to meet...

UAL : 33.86 (+0.86%)
FIT : 7.04 (+0.28%)
BYND : 142.43 (-6.20%)
MYOV : 13.80 (-7.26%)
NKLA : 18.31 (-7.48%)
UNFI : 14.57 (-8.02%)
SUI : 137.63 (-0.88%)
SHAREHOLDER ALERT: Investigation of Myovant Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - September 29, 2020) - Holzer & Holzer, LLC is investigating whether Myovant Sciences Ltd. (NYSE: MYOV) ("Myovant" or the "Company") complied with federal securities...

MYOV : 13.80 (-7.26%)
Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer

-- Relugolix had a similar rate of castration resistance-free survival in the subgroup of men with metastatic disease compared to leuprolide acetate (74% vs. 75%, respectively) and did not achieve statistical...

MYOV : 13.80 (-7.26%)
Is the Options Market Predicting a Spike in Myovant Sciences (MYOV) Stock?

Investors need to pay close attention to Myovant Sciences (MYOV) stock based on the movements in the options market lately.

MYOV : 13.80 (-7.26%)
Myovant Sciences Launches "Forward for Health Equity" Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

-- Prostate cancer and uterine fibroids disproportionately impact Black Americans; racial disparities are exacerbated by inequities in healthcare access and COVID-19 pandemic

MYOV : 13.80 (-7.26%)
Thinking about buying stock in Cassava Sciences, Myovant Sciences, Sesen Bio, JinkoSolar, or Square?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SAVA, MYOV, SESN, JKS, and SQ.

JKS : 58.30 (-4.46%)
MYOV : 13.80 (-7.26%)
SQ : 154.88 (-8.82%)
Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study

-- Relugolix combination therapy maintained bone mineral density through one year, consistent with bone mineral density changes observed in untreated women

MYOV : 13.80 (-7.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral...

See More

Key Turning Points

2nd Resistance Point 15.45
1st Resistance Point 14.63
Last Price 13.80
1st Support Level 13.29
2nd Support Level 12.77

See More

52-Week High 23.04
Fibonacci 61.8% 16.02
Fibonacci 50% 13.85
Last Price 13.80
Fibonacci 38.2% 11.68
52-Week Low 4.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar